Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Buys 237,616 Shares

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi bought 237,616 shares of the stock in a transaction on Wednesday, August 5th. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the purchase, the chief executive officer owned 4,793,684 shares in the company, valued at approximately $4,793,684. This represents a 5.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ivor Elrifi also recently made the following trade(s):

• On Tuesday, August 4th, Ivor Elrifi purchased 83,807 shares of Tiziana Life Sciences stock. The stock was bought at an average cost of $0.97 per share, with a total value of $81,292.79.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The shares were bought at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Stock Down 1.6%

Shares of TLSA opened at $0.97 on Friday. The company’s 50 day moving average price is $1.14 and its 200 day moving average price is $1.30. Tiziana Life Sciences Ltd has a 52 week low of $0.87 and a 52 week high of $2.53.

Analysts Set New Price Targets

TLSA has been the topic of a number of research reports. Wall Street Zen downgraded shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, Zacks Research raised Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Rachor Investment Advisory Services LLC bought a new stake in Tiziana Life Sciences in the fourth quarter worth $25,000. Cubist Systematic Strategies LLC bought a new position in Tiziana Life Sciences during the first quarter valued at about $25,000. Marshall Wace LLP bought a new position in Tiziana Life Sciences during the second quarter valued at about $39,000. HRT Financial LP acquired a new stake in shares of Tiziana Life Sciences in the fourth quarter worth about $36,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Tiziana Life Sciences in the fourth quarter worth about $59,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.